Navigation Links
CMC Biologics Honored as Finalist for Washington's Manufacturing Company of the Year Award
Date:5/3/2012

SEATTLE, May 3, 2012 /PRNewswire/ -- CMC Biologics, a leading contract manufacturing organization (CMO) known and respected for its technical excellence in process development and cGMP manufacture, has been named a finalist for  the 2012 Manufacturing Company of the Year – Large Category.   The Seattle Business Magazine's Washington Manufacturing Awards, in partnership with Impact Washington, brought together nearly 300 leaders in manufacturing from around the state.

(Logo: http://photos.prnewswire.com/prnh/20110502/SF93356LOGO )

"CMC Biologics has been operating in Washington state as a thriving biopharmaceutical contract manufacturer since 2007.  With nearly 450 talented and hardworking employee's world-wide, we continue to grow and to hire locally and globally at our manufacturing facility in Bothell, as well as our facility in Copenhagen, Denmark," said Gustavo Mahler, Chief Operations Officer for the company. "We are positioned to be the leader among CMO's in customer satisfaction and technical excellence, and are excited to be considered a top manufacturer among dozens of companies in this competition."

"The life sciences industry is one of the fastest growing economic drivers of our state, and companies like CMC Biologics as a biopharmaceutical manufacturer, are providing the people of Washington with good jobs and a prosperous future," stated Gubernatorial Candidate Jay Inslee.  "I'd like to congratulate the team at CMC Biologics for their hard work and dedication as a finalist for Washington's Manufacturer of the Year."

As the state's largest biopharmaceutical manufacturer, CMC Biologics' contribution to the economy is significant.  In 2011, CMC Biologics completed the expansion of a state-of the art stainless steel biopharmaceutical manufacturing facility, utilizing local contractors and suppliers.  This expansion added significant production capacity to accommodate growing demand for cGMP commercial manufacture of biopharmaceuticals and to support commercial manufacturing and was the second stage of a major manufacturing expansion plan that started with the construction of a multi‑purpose single-use facility completed in 2010.

About CMC Biologics

CMC Biologics is a leading contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing solutions to clients around the world, from its facilities in Europe and the USA.  The company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and in-market production.  The company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing.  Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production.  CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes.  CMC Biologics is located in Copenhagen, Denmark, and Seattle, Washington. Visit www.cmcbio.com  to learn more.

 

 


'/>"/>
SOURCE CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
2. Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy
3. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
4. Savient Submits Biologics License Application (BLA) for pegloticase
5. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
6. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
7. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
8. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
9. Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
10. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
11. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... 2017  Ascendis Pharma A/S (Nasdaq: ASND), a ... to address significant unmet medical needs in rare ... year ended December 31, 2016. ... as we broadened our pipeline and pursued our ... company with an initial focus on endocrinology," said ...
Breaking Biology Technology:
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/9/2017)... The biomass boiler market report by Transparency Market Research ... in terms of revenue (US$ Mn) based on the ... boilers has been segmented on the basis of feedstock ... based on feedstock type, has been segmented into woody ... urban residues, and others. On the basis of product ...
Breaking Biology News(10 mins):